COVID-19 Resources

The American Partnership for Eosinophilic Disorders (APFED) is closely monitoring developments regarding the novel coronavirus (COVID-19) outbreak and the potential impact on the higher-risk patients in the eosinophil-associated disease community. This is a rapidly changing situation and we encourage you to follow updates on the Centers for Disease Control and Prevention (CDC)’s website and your state health department website.

Presentation of Interest

COVID-19, Vaccination and Eosinophilia by Dr. Paneez Khoury, NIH
To access the presentation, register for the Eos Connection 2021 Conference and navigate to the Theater. 

Research about COVID-19 and Eosinophilic Disorders

Learn more about the latest published research on COVID-19 and Eosinophil-associated diseases.

Pfizer/BioNTech COVID Vaccine

COVID-19 has spread around the world resulting in the World Health Organization (WHO) declaring a public health emergency of international concern and the United States Health and Human Services Secretary declaring a public health emergency.

The American College of Allergy, Asthma and Immunology COVID-19 Vaccine Task Force published recommended guidance related to risk of an allergic reaction on vaccination. If you have questions about vaccination and whether or not you are a candidate for the Pfizer/BioNTech COVID vaccine, please speak to your health care provider.


Potential Impact on People with Eosinophil-Associated Diseases

There is not enough information as of yet, however, it appears that people with chronic health conditions, including those who have pulmonary or cardiac eosinophilic disorders, and those who take systemic corticosteroids and/or other immunosuppressive medications (e.g., methotrexate, cyclosporin, rituximab infusions) may be at higher risk of developing complications or more severe infection with COVID-19. Individuals should contact their healthcare provider if they have symptoms consistent with COVID-19.

UPDATE (January 2021): Increased research studies suggest that eosinophilic gastrointestinal diseases are not risk factors for COVID-19.

APFED encourages everyone to follow COVID-19 guidance from the CDC and the WHO and to be alert to local quarantine practices in their communities.


CDC Information about COVID-19


Medical Reviewers: Gerald J. Gleich, MD, University of Utah Health; Michael E. Wechsler, MD, National Jewish Health; Praveen Akuthota, MD, UC San Diego Health.

Other Resources and Updates